Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).

This study has been terminated.
(poor enrollment)
Sponsor:
Collaborator:
Alcon Research
Information provided by:
Manhattan Eye, Ear & Throat Hospital
ClinicalTrials.gov Identifier:
NCT00211471
First received: September 13, 2005
Last updated: May 4, 2007
Last verified: May 2007
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: May 2007
  Estimated Primary Completion Date: No date given